Breaking News Instant updates and real-time market news.

GILD

Gilead

$74.87

0.33 (0.44%)

04:55
11/30/16
11/30
04:55
11/30/16
04:55

Gilead management to meet with Leerink

Meeting to be held in New York on November 30 hosted by Leerink.

  • 30

    Nov

  • 01

    Dec

  • 02

    Dec

  • 03

    Dec

GILD Gilead
$74.87

0.33 (0.44%)

11/17/16
LEER
11/17/16
NO CHANGE
Target $89
LEER
Market Perform
Gilead myelofibrosis data miss may open path for M&A, says Leerink
Leerink analyst Geoffrey Porges notes that Gilead (GILD) released disappointing Phase III data for its JAK 1/2 inhibitor momelotinib in myelofibrosis. The company indicated that they plan to discuss these results with regulatory authorities to determine the next steps, but it seems likely that momelotinib will be written off, he adds. However, Porges believes that this disappointment restores Incyte (INCY) to the list of feasible candidates for acquisition by Gilead, since it would no longer face the obligation to divest one of the overlapping JAK programs. He reiterates a Market Perform rating and $89 price target on Gilead's shares.
11/17/16
LEER
11/17/16
NO CHANGE
Target $115
LEER
Outperform
Incyte price target raised to $115 from $101 at Leerink
Leerink analyst Michael Schmidt raised his price target for Incyte (INCY) to $115 from $101 after Gilead (GILD) reported disappointing top-line results from two Phase III studies evaluating momelotinib, its JAK1/2 inhibitor for patients with myelofibrosis. The analyst believes that the removal of this uncertainty on the revenue outlook of Incyte's key commercial product, combined with increasing prospects of a repatriation holiday should make the company more attractive as an acquisition target. He reiterates an Outperform rating on Incyte's shares.
11/17/16
BMOC
11/17/16
NO CHANGE
BMOC
Incyte drug won't have 'meaningful competition,' says BMO Capital
BMO Capital analyst M. Ian Somaiya says that "mixed data" on Gilead's (GILD) momelotinib in myelofibrosis eliminates any "meaningful competition" faced by Incyte's (INCY) Jakafi in the disease. The analyst raised his price target on Incyte to $126 from $121 and keeps an Outperform rating on the shares.
11/18/16
GABE
11/18/16
NO CHANGE
Target $99
GABE
Buy
Incyte, Regeneron among Gilead M&A options after latest setback, says Gabelli
Gabelli analyst Jing He noted Gilead's (GILD) "mixed" results from its Phase III trials evaluating momelotinib, which showed that the drug is not superior to Incyte's (INCY) Jakafi. Commenting on Gilead's potential path after momelotinib's "disappointing" results and several other pipeline setbacks this year, He suggested that Gilead could look to buy Incyte, which looks like "Regeneron lite," or simply buy Regeneron (REGN) itself. The analyst said Gilead could alternately target an orphan drug company such as Alexion (ALXN), Vertex (VRTX) or BioMarin (BMRN). She keeps a Buy rating and $99 per share private market value on Gilead shares, as she expects M&A to be a catalyst for the stock.

TODAY'S FREE FLY STORIES

HCLP

Hi-Crush Partners

$22.97

1.5705 (7.34%)

12:26
02/22/17
02/22
12:26
02/22/17
12:26
Upgrade
Hi-Crush Partners rating change  »

Wunderlich upgrades…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 28

    Feb

PAA

Plains All American

$30.57

-0.67 (-2.14%)

12:26
02/22/17
02/22
12:26
02/22/17
12:26
Options
Plains All American call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

  • 08

    Aug

  • 08

    Nov

12:25
02/22/17
02/22
12:25
02/22/17
12:25
General news
Euro$ interest rate futures stalled out »

Euro$ interest rate…

12:25
02/22/17
02/22
12:25
02/22/17
12:25
Conference/Events
Forecasters Club of New York to hold a luncheon meeting »

Federal Reserve Governor…

USPH

U.S. Physical Therapy

$74.55

-1.55 (-2.04%)

12:25
02/22/17
02/22
12:25
02/22/17
12:25
Conference/Events
CFA Society of Houston to hold a luncheon meeting »

Chris Reading, CEO of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 21

    Mar

  • 29

    Mar

  • 11

    Apr

  • 12

    Apr

PUGOY

Peugeot

$19.40

-0.215 (-1.10%)

, GM

General Motors

$37.86

0.05 (0.13%)

12:23
02/22/17
02/22
12:23
02/22/17
12:23
Periodicals
PSA Group targets up to $2.1B in cost savings from Opel deal, Reuters says »

Peugeot (PUGOY) parent…

PUGOY

Peugeot

$19.40

-0.215 (-1.10%)

GM

General Motors

$37.86

0.05 (0.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

SCOR

comScore

$24.42

0.12 (0.49%)

12:21
02/22/17
02/22
12:21
02/22/17
12:21
Conference/Events
comScore to host business news update conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 24

    Feb

BA

Boeing

$175.52

-0.04 (-0.02%)

, LMT

Lockheed Martin

$264.87

-0.79 (-0.30%)

12:19
02/22/17
02/22
12:19
02/22/17
12:19
Periodicals
Key lawmaker: Trump jet competition 'doesn't make sense,' Bloomberg reports »

Speaking in a Bloomberg…

BA

Boeing

$175.52

-0.04 (-0.02%)

LMT

Lockheed Martin

$264.87

-0.79 (-0.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

$NSD

NASDAQ Market Internals

12:17
02/22/17
02/22
12:17
02/22/17
12:17
Technical Analysis
NASDAQ Market Internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

12:17
02/22/17
02/22
12:17
02/22/17
12:17
Technical Analysis
NYSE Market Internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNJ

Johnson & Johnson

$119.46

-0.2 (-0.17%)

12:17
02/22/17
02/22
12:17
02/22/17
12:17
Conference/Events
Johnson & Johnson hs a conference call hosted by JPMorgan »

JPMorgan Analyst…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 24

    Feb

  • 09

    Mar

  • 14

    Mar

  • 27

    Mar

12:15
02/22/17
02/22
12:15
02/22/17
12:15
General news
FX Action: USD-JPY »

FX Action: USD-JPY traded…

UN

Unilever; also tag UL

$46.74

1.65 (3.66%)

, UL

Unilever; also tag UN

$46.99

2.12 (4.72%)

12:14
02/22/17
02/22
12:14
02/22/17
12:14
General news
On The Fly: Top stock stories at midday »

Stocks opened in negative…

UN

Unilever; also tag UL

$46.74

1.65 (3.66%)

UL

Unilever; also tag UN

$46.99

2.12 (4.72%)

KHC

Kraft Heinz

$94.87

-1.78 (-1.84%)

TJX

TJX

$76.00

-0.245 (-0.32%)

GRMN

Garmin

$50.45

-0.36 (-0.71%)

TOL

Toll Brothers

$34.04

2.05 (6.41%)

DEPO

Depomed

$15.77

-0.7 (-4.25%)

CHS

Chico's

$14.93

0.635 (4.44%)

PZZA

Papa John's

$85.63

-0.38 (-0.44%)

TXRH

Texas Roadhouse

$47.79

-0.45 (-0.93%)

FSLR

First Solar

$36.62

1.78 (5.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 22

    Feb

  • 27

    Feb

  • 28

    Feb

  • 01

    Mar

  • 19

    Mar

INGIY

Ingenico

$16.94

0.02 (0.12%)

12:06
02/22/17
02/22
12:06
02/22/17
12:06
Hot Stocks
Ingenico finalizes acquisition of TechProcess; terms not disclosed »

Ingenico Group announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Mar

HCLP

Hi-Crush Partners

$23.05

1.65 (7.71%)

12:06
02/22/17
02/22
12:06
02/22/17
12:06
Upgrade
Hi-Crush Partners rating change  »

Hi-Crush Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 28

    Feb

12:05
02/22/17
02/22
12:05
02/22/17
12:05
General news
Treasury's $13 B 2-year FRN reopening was mixed »

Treasury's $13 B…

NFX

Newfield Exploration

$39.62

-2.87 (-6.75%)

12:01
02/22/17
02/22
12:01
02/22/17
12:01
Options
Newfield Exploration puts active as shares fall on earnings »

Newfield Exploration puts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

11:59
02/22/17
02/22
11:59
02/22/17
11:59
Conference/Events
JPMorgan biotech/biopharma analysts hold an analyst/industry conference call »

SMid Biotech Analyst…

TWTR

Twitter

$16.33

-0.09 (-0.55%)

11:59
02/22/17
02/22
11:59
02/22/17
11:59
Hot Stocks
Twitter director of finance David Bicknell resigns »

David Bicknell, director…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 22

    Feb

  • 23

    Feb

  • 28

    Feb

  • 19

    Mar

PSX

Phillips 66

$78.29

-0.7425 (-0.94%)

11:56
02/22/17
02/22
11:56
02/22/17
11:56
Options
Phillips 66 put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DLB

Dolby

11:54
02/22/17
02/22
11:54
02/22/17
11:54
Conference/Events
Dolby management to meet with William Blair »

Group luncheon to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 27

    Feb

  • 28

    Mar

TREX

Trex Company

$66.58

-4.57 (-6.42%)

11:53
02/22/17
02/22
11:53
02/22/17
11:53
Conference/Events
Trex Company management to meet with Stephens »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

P

Pandora

$13.08

-0.065 (-0.49%)

11:52
02/22/17
02/22
11:52
02/22/17
11:52
Conference/Events
Pandora management to meet with B. Riley »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 23

    Feb

  • 28

    Feb

  • 19

    Mar

CARB

Carbonite

$19.65

0.05 (0.26%)

11:50
02/22/17
02/22
11:50
02/22/17
11:50
Conference/Events
Carbonite management to meet with Lake Street »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 23

    Feb

  • 27

    Feb

RP

RealPage

$34.35

-0.2 (-0.58%)

11:50
02/22/17
02/22
11:50
02/22/17
11:50
Hot Stocks
RealPage announces new multi-year agreement with Morgan Properties »

RealPage announces that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 27

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.